Camrelizumab
- Generic Name
- Camrelizumab
- Drug Type
- Biotech
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06546280
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Biological: CircFam53B-219aa DC vaccine
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 48
- Registration Number
- NCT06530082
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 33
- Registration Number
- NCT06516445
- Locations
- 🇨🇳
Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
- Conditions
- BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT06516289
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
- Conditions
- RWSGastric CancerPD-1 Immunotherapy
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
- Target Recruit Count
- 504
- Registration Number
- NCT06485271
- Locations
- 🇨🇳
Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
- Conditions
- Unresectable Gallbladder Cancer
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-05-21
- Target Recruit Count
- 37
- Registration Number
- NCT06423170
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
- Conditions
- TP53 MutationEndometrial CarcinomaRecurrent or Metastatic
- Interventions
- Radiation: External irradiation
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 117
- Registration Number
- NCT06413992
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
- Conditions
- T-lymphoblastic LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT06376721
- Locations
- 🇨🇳
Liang Wang, Beijing, Beijing, China
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 57
- Registration Number
- NCT06363825
- Locations
- 🇨🇳
Xinhua Chen, Fuzhou, China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 111
- Registration Number
- NCT06360042
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.